CordenPharma introduces new LNP Starter Kits for mRNA Formulation
CordenPharma has introduced new starter kits to facilitate formulation in the creation of mRNA-based therapeutics
CordenPharma International's promotes the latest Lipid NanoParticle (LNP) Starter Kits. These kits are designed for creating messenger RNA (mRNA)-based therapeutics like mRNA vaccines or gene therapies. The starter kits are created to equip researchers and developers with the necessary components to develop and enhance their own LNPs for mRNA delivery.
The new LNP kits contain four essential lipids: ionizable lipids, helper lipids, sterols, and PEGylated lipids. Moreover, the kits are put together using materials from large commercial sources. These features help prevent negative consequences and protect valuable payload from being compromised by poor lipid quality. They also reduce the risk of switching lipid sources from the R&D phase to clinical phases, as stated in a company press release.
The kits are created to simplify the process of formulation screening and produce LNPs that can achieve effective transfection in various cell types, such as immortalized and/or primary cell cultures. These kits are perfect for animal in-vivo applications, such as pharmacokinetic/pharmacodynamic studies and mRNA transfection efficacy proof-of-concept studies. They have also been tested with green fluorescent protein-mRNA as cargo and have successfully implemented testing for synthetic RNAs (such as small interfering RNA) and DNA.
Users can adjust the LNP formulation process to produce nanoparticles with specific physicochemical characteristics, including a polydispersity index of ≤0.2 and a size range of 30–150 nm. These characteristics depend on factors like LNP reaction conditions, lipid composition, and cargo.
CordenPharma is excited to present the new LNP Starter Kit concept, showcasing a strong collaboration between our Lipid and LNP expertise. This initiative aims to speed up time to market and offer efficient compositions for LNP-based drug development, enhancing the delivery of RNA, DNA, and gene therapy payloads for different therapeutic indications, ultimately impacting patient lives positively.
Source: CordenPharma International
